Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab Injection Site PK Study in Healthy Subjects
NCT06462118Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of astegolimab in asthma and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Genentech. Primary endpoints: Area under the curve from Hour 0 to the time of last measurable concentration at 85 days, Area under the curve extrapolated to infinity at 85 days and 1 more. Started Jun 2024; status: completed.
02
Drugs
astegolimab
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06462118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462118.